TB-500

Overview

TB-500 is the synthetic, commercially available form of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide that is one of the most abundant intracellular proteins in the human body. Thymosin Beta-4 was first isolated from the thymus gland in 1981 by Allan Goldstein and colleagues, and it has since been identified in virtually every cell and tissue type, with particularly high concentrations in wound fluid, blood platelets, and white blood cells.

The "TB-500" designation is a commercial/research name rather than an official scientific nomenclature. It refers to synthetic preparations of the full Thymosin Beta-4 sequence or its active fragments. The most commonly referenced active region is the central actin-binding domain, specifically the sequence LKKTETQ (amino acids 17–23), which has been identified as the primary mediator of many of Tβ4's biological activities.

What distinguishes Thymosin Beta-4 from many other research peptides is the extraordinary depth of its scientific literature. With over 1,000 published studies spanning four decades, Tβ4 is one of the most well-characterized peptides in biomedical research. It has been the subject of actual human clinical trials (particularly for wound healing and ophthalmological applications), giving it a level of clinical evidence that many research peptides lack.

Amino Acid Sequence

The full Thymosin Beta-4 sequence (43 amino acids):

Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

• Molecular formula: C₂₁₂H₃₅₀N₅₆O₇₈S
• Molecular weight: 4,963.50 g/mol (free acid)
• N-terminus: Acetylated (Ac-Ser)
• Active domain: LKKTETQ (residues 17–23)
• CAS Number: 77591-33-4

The acetylated N-terminal serine is a naturally occurring post-translational modification that contributes to the peptide's stability.

Mechanism of Action

Thymosin Beta-4's mechanisms are among the most well-characterized of any research peptide, owing to decades of study across multiple laboratories worldwide.

Actin Sequestration and Cell Migration

The primary known function of Tβ4 is as a G-actin sequestering protein. Actin is one of the most abundant proteins in eukaryotic cells and is the building block of the cytoskeleton — the internal scaffolding that gives cells their shape and enables movement.

Tβ4 binds monomeric G-actin (globular actin) in a 1:1 complex, preventing its polymerization into F-actin (filamentous actin) filaments. This sequestration:

• Maintains a pool of available actin monomers for rapid cytoskeletal remodeling
• Enables rapid cell migration when needed (e.g., toward an injury site)
• Facilitates cell shape changes necessary for tissue repair
• Regulates the balance between cell motility and structural stability

When tissue damage occurs, Tβ4 is released from platelets and damaged cells, creating a concentration gradient that promotes directed cell migration toward the injury.

Anti-Inflammatory Pathways

Tβ4 has demonstrated significant anti-inflammatory properties through multiple mechanisms:

• NF-κB modulation — Tβ4 has been shown to inhibit NF-κB activation, a master regulator of inflammatory gene expression
• Cytokine regulation — Reduced production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in multiple study models
• Inflammatory cell infiltration — Reduced neutrophil and macrophage infiltration in tissue injury models
• Oxidative stress reduction — Decreased reactive oxygen species (ROS) production in inflamed tissues

Angiogenesis

Similar to BPC-157, Tβ4 promotes the formation of new blood vessels:

• Upregulation of VEGF and angiopoietin-1
• Direct promotion of endothelial cell migration and tube formation
• Enhanced collateral vessel formation in ischemic tissue
• Activation of the Akt/eNOS signaling pathway in endothelial cells

Anti-Fibrotic / Anti-Scarring Effects

One of Tβ4's most clinically relevant properties is its ability to reduce scar formation:

• Modulation of collagen deposition patterns — promoting organized collagen over disordered scar tissue
• Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs)
• Promotion of regenerative healing over fibrotic scarring in skin wound models
• Potential reduction of hypertrophic scar formation

Hair Follicle Stem Cell Activation

Tβ4 has been shown to promote hair growth through activation of hair follicle stem cells:

• Stimulation of follicular stem cell migration and differentiation
• Acceleration of hair follicle cycling from telogen (resting) to anagen (growth) phase
• This mechanism was first described by Philp et al. (2004) and has been replicated in subsequent studies

Cardioprotective Effects

Significant research has focused on Tβ4's effects on cardiac tissue:

• Protection of cardiac myocytes from ischemic damage
• Activation of cardiac progenitor cells (Akt-positive cells)
• Promotion of neovascularization in ischemic myocardium
• Improvement in cardiac function following myocardial infarction in animal models
• These findings led to human clinical trials (discussed below)

Research Summary

Area of Study	Key Finding	Notable Reference
Wound healing	Accelerated full-thickness wound closure in rats and mice; reduced inflammation and scarring	Malinda et al., Journal of Investigative Dermatology, 1999
Corneal healing	Promoted corneal epithelial wound healing; reduced inflammation and scarring after alkali burns	Sosne et al., Experimental Eye Research, 2002
Cardiac repair	Improved cardiac function post-MI in mice; activated cardiac progenitor cells	Bock-Marquette et al., Nature, 2004
Hair growth	Stimulated hair growth through follicular stem cell activation	Philp et al., FASEB Journal, 2004
Brain injury (TBI)	Improved neurological outcomes after TBI in rats; promoted neurogenesis and angiogenesis in the brain	Xiong et al., Journal of Neuroscience Research, 2011
Spinal cord injury	Improved functional recovery after spinal cord contusion in rats	Zhang et al., PLoS ONE, 2012
Dry eye	Phase II clinical trial: RGN-259 (Tβ4 eye drops) showed efficacy for dry eye disease	Dunn et al., Clinical Ophthalmology, 2010
Pressure ulcers	Phase I/II trial: Topical Tβ4 accelerated healing of pressure ulcers and venous stasis ulcers	Treadwell et al., Annals of the New York Academy of Sciences, 2012
Sepsis	Reduced mortality and organ damage in cecal ligation and puncture sepsis model	Badamchian et al., Expert Opinion on Biological Therapy, 2003
Liver fibrosis	Anti-fibrotic effects in carbon tetrachloride-induced liver fibrosis model	Kim & Bhang, International Journal of Molecular Sciences, 2017
Periodontal disease	Enhanced periodontal tissue regeneration in rat periodontitis model	Fakhari et al., Growth Factors, 2017
Muscle injury	Accelerated skeletal muscle repair following laceration injury	Kaur et al., British Journal of Sports Medicine, 2014

Human Clinical Trials

Unlike many research peptides, TB-500/Thymosin Beta-4 has reached human clinical trials:

RegeneRx Biopharmaceuticals (RGN-259)

• Ophthalmology: Phase II trials for neurotrophic keratopathy and dry eye disease using topical Tβ4 eye drops (RGN-259). Results showed improved corneal wound healing and patient-reported outcomes
• Dermatology: Phase I/II trials for chronic wound healing (pressure ulcers, venous stasis ulcers) using topical Tβ4 (RGN-137). Preliminary results showed accelerated wound closure
• Cardiac: Phase I trial for acute myocardial infarction. The cardiac program explored systemic Tβ4 administration post-MI

These trials provide human safety and preliminary efficacy data that is unavailable for most research peptides.

Pharmacokinetics

• Estimated plasma half-life: 2–3 hours for circulating Tβ4 (though tissue-level activity may persist longer)
• Distribution: Widely distributed; high concentrations in wound fluid, platelets, and white blood cells
• Metabolism: Processed by various peptidases; breakdown products may retain biological activity
• Dosing patterns in research: Typically studied at higher loading frequencies initially (e.g., twice weekly), followed by reduced maintenance dosing (weekly)

The relatively short plasma half-life is somewhat offset by the peptide's ability to trigger downstream signaling cascades and gene expression changes that persist well beyond its presence in circulation.

Administration and Dosing in Research

TB-500 is most commonly administered via subcutaneous injection:

• Typical research vial sizes: 2 mg, 5 mg, and 10 mg
• Reconstitution: Standard bacteriostatic water protocol (see Reconstitution)
• Storage: Lyophilized at -20°C long-term; reconstituted at 2–8°C for up to 3–4 weeks

Common research dosing patterns discussed in the community:

• Loading phase: Higher frequency for 4–6 weeks
• Maintenance phase: Reduced frequency thereafter
• Note: There are no established human dosing guidelines; research doses are based on animal study extrapolation

TB-500 vs. Thymosin Beta-4: Terminology

There is sometimes confusion about the distinction between TB-500 and Thymosin Beta-4:

	TB-500	Thymosin Beta-4
Origin	Commercial/research term	Scientific name
Sequence	Full Tβ4 or active fragments	Full 43-amino-acid protein
Source	Synthetic	Naturally occurring in body
Clinical trials	No (under the TB-500 name)	Yes (under Tβ4 and brand names like RGN-259)
Availability	Research peptide suppliers	Pharmaceutical-grade for trials

In practice, most products sold as "TB-500" contain the full Thymosin Beta-4 sequence, though some may be fragments. Quality and content can vary between suppliers.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for research peptides. Always consult a qualified healthcare professional.

Standard Protocol (Loading + Maintenance)

Phase	Dose	Frequency	Duration
Loading	2.0–2.5 mg (2,000–2,500 mcg)	Twice weekly	Weeks 1–4
Maintenance	2.0–2.5 mg (2,000–2,500 mcg)	Once weekly	Weeks 5–12

Reconstitution (5 mg vial)

• Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration
• At this concentration: 1 unit = 25 mcg on a U-100 insulin syringe
• 2,500 mcg (2.5 mg) = 100 units (full 1 mL syringe) = 1 full vial per 2 doses

Cycle Guidelines

• Cycle length: 8–12 weeks total (4 weeks loading + 4–8 weeks maintenance)
• Injection timing: Consistent days (e.g., Monday/Thursday for loading, Monday for maintenance)
• Injection site: Subcutaneous; TB-500 is considered systemically active regardless of injection location
• Rest period: 4–6 weeks off between cycles

Common Discussion Topics

In the research and biohacking community, TB-500 is frequently discussed regarding:

1. Combined use with BPC-157 — The "BPC-157 + TB-500 stack" is one of the most commonly discussed peptide combinations for tissue repair. The rationale is that their mechanisms are complementary: BPC-157 acts through the nitric oxide system and growth factor modulation, while TB-500 works through actin regulation and anti-inflammatory pathways
2. Recovery from sports injuries — Tendon, ligament, and muscle injuries
3. Systemic vs. local effects — Unlike some peptides, TB-500 is generally considered to have systemic effects regardless of injection site, due to its mechanism (actin sequestration is a fundamental cellular process)
4. Dosing protocols — Loading vs. maintenance phase discussions
5. Hair regrowth applications — Based on the published stem cell activation research
6. Cardiac and neuroprotective applications — Growing interest based on published clinical data

Safety Profile

Animal Studies

• No significant adverse effects reported in the extensive preclinical literature
• No reported organ toxicity at studied doses
• The naturally occurring nature of Tβ4 (present in all cells) suggests fundamental biological compatibility

Human Clinical Trial Data

• Phase I and II trials reported no drug-related serious adverse events
• Topical applications (eye drops, wound gels) were well-tolerated
• The most common reported events were mild and transient

Theoretical Concerns

• As a promoter of cell migration and angiogenesis, there have been theoretical questions about whether Tβ4 could promote tumor growth or metastasis. Published research has been mixed — some studies suggest anti-tumor effects, while others have found elevated Tβ4 levels in certain tumor types. This remains an active area of investigation

Regulatory Status

• Not FDA-approved for any indication as of 2026
• RGN-259 (topical Tβ4 eye drops) received FDA Breakthrough Therapy Designation for neurotrophic keratopathy
• Tβ4 is on the WADA (World Anti-Doping Agency) prohibited list under peptide hormones and growth factors
• Classified as a research chemical by most regulatory bodies

Related Compounds

• BPC-157 — complementary tissue repair peptide; often used in combination
• Thymosin Alpha-1 (Tα1) — another thymic peptide, primarily studied for immune modulation; FDA-approved in some countries as Zadaxin
• GHK-Cu — copper peptide studied for wound healing and skin regeneration
• TB-4-Ac (Ac-SDKP) — the N-terminal tetrapeptide fragment of Tβ4, studied for anti-fibrotic properties
• Thymalin — a thymic extract containing multiple peptides including thymosin fractions